The Appetite For GLP-1 Is Growing. Here’s What This Means for Employers

Promoting self-care and equipping employees with supportive tools

By Lorna Borenstein, Grokker

Everyone seems to be talking about GLP-1s. This class of medications, which were initially created to treat type 2 diabetes, are quickly becoming known as “miracle drugs” for those looking to lose weight. In the last year alone, medications like Ozempic and Mounjauro have been embraced by celebrities and praised by the medical community for their ability to help people shed pounds without overhauling their diet or spending countless hours at the gym. In fact, current research estimates that 7% of the US population will be taking GLP-1 medications by 2035. GLP-1s, the shorthand moniker for Glucagon-like peptide-1 agonists, literally make weight loss as simple as getting an injection. And when you look at it this way, who wouldn’t see them as the ideal solution for weight loss?